October 20, 2023
FastBack Bio
FastBack Bio is a biotechnology company with a novel CAR-T platform. FastBack Bio will develop CAR-T therapeutics with a novel co-stimulatory domain, M83, from its in-licensed platform.
FastBack Bio is a biotechnology company with a novel CAR-T platform. FastBack Bio will develop CAR-T therapeutics with a novel co-stimulatory domain, M83, from its in-licensed platform.
Promaxo develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients' lives and redefine the standard of care.
neuro42, Inc. is a medtech Company advancing futuristic technologies for screening, diagnosis, and targeted treatment of neurological conditions.
Inceptor Bio is developing next-generation cell therapy programs with a focus on chimeric antigen receptor (CAR) constructs.
EnteroBiotix is a clinical-stage Microbiome biotech focused on developing therapeutics for Hepatic Encephalopathy and Graft vs. Host Disease.
Amylyx is a pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders.